Table 1.
Comparison of the clinical characteristics, tacrolimus daily dose, tacrolimus blood levels, and C/D ratio of the study population between CYP3A5 expressors and non-expressors.
| Characteristics | Non-expressors (*3/*3) n = 41 | Expressors (*1/*3, *1/*1) n = 18 | P value |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 35 (85.37%) | 13 (72.2%) | 0.2841 |
| Female | 6 (14.63%) | 5 (27.8%) | |
| Onset of CKD, years, mean (range) (SD) | 27.2 (9–55) | 31.2 (14–65) | 0.2403 |
| Onset at transplantation, years, mean (range) (SD) | 29.2 (10–55) | 32.8 (14–67) | 0.2983 |
| Time waiting for transplant, years, mean (range) (SD) | 2 (0–6) | 1.56 (0–4) | 0.1965 |
| Graft rejection, n (%) | |||
| Yes | 8 (19.5%) | 6 (33.3%) | 0.3224 |
| No | 33 (80.5%) | 12 (66.7%) | |
| Family history, n (%) | |||
| Yes | 3 (7.3%) | 2 (11.1%) | 0.6359 |
| No | 38 (92.7%) | 16 (88.9%) | |
| Donor type, n (%) | |||
| Living Related | 33 (80.5%) | 14 (77.8%) | 1.0000 |
| Living unrelated | 8 (19.5%) | 4 (22.2%) | |
| Initial Tac D, mg/day, mean (range) (SD) | 6.76 (2–11) | 9.86 (6–14) | <0.0001 |
| 1-year Tac D, mg/day, mean (range) (SD) | 4.21 (1.5–10.5) | 7.81 (2.5–13) | <0.0001 |
| Initial Tac C, ng/ml, mean (range) (SD) | 7.09 (2–22.6) | 5.89 (2–13.5) | 0.3035 |
| 1-year Tac C, ng/mL, mean (range) (SD) | 7.39 (3.3–11.7) | 7.15 (4.9–9.9) | 0.6373 |
| Initial C/D ratio, ng/ml per mg/day, mean (range) (SD) | 1.50 (0.2–9.4) | 0.64 (0.18–1.5) | 0.0586 |
| 1-year C/D ratio, ng/ml per mg/day, mean (range) (SD) | 2.10 (0.6–5.8) | 1.10 (0.63–2.84) | 0.0003 |
D, tacrolimus daily dose; C, tacrolimus blood concentration; SD, standard deviation.
Bolded data are those which are statistically significant.